Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
9 studies found for:    MPACT
Show Display Options
Rank Status Study
1 Recruiting Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy
Condition: Head and Neck Neoplasms
Intervention: Other: MPACT
2 Recruiting A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup
Conditions: Osteoarthritis;   Arthritis;   Avascular Necrosis;   Fracture of the Femoral Neck or Head;   Congenital Hip Dysplasia
Intervention: Device: Mpact Acetabular Shell
3 Recruiting Bone Fixation of Mpact Double Mobility Cup
Condition: Total Hip Replacement
Intervention: Device: Mpact Double Mobility cup
4 Recruiting Mpact Cup Performance After Total Hip Arthroplasty
Condition: Total Hip Replacement
5 Completed Impact of Myfortic on Gastrointestinal (GI) Prophylaxis in Maintenance Renal Transplant Patients
Condition: Kidney Transplantation
Intervention: Drug: GI medication
6 Completed Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests
Condition: Coronary Disease
7 Completed A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
Condition: Pancreatic Cancer
Intervention: Drug: ABI-007
8 Recruiting A Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Condition: Pancreatic Carcinoma Metastatic
Interventions: Drug: Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4;   Drug: Gemcitabine 1000 weeks 1,2,3/4
9 Recruiting Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors
Conditions: Advanced Malignant Solid Neoplasm;   Recurrent Malignant Solid Neoplasm
Interventions: Drug: Carboplatin;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide;   Drug: Trametinib;   Drug: Veliparib;   Drug: WEE1 Inhibitor AZD1775

Study has passed its completion date and status has not been verified in more than two years.